Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Depreciation and Depletion (2018 - 2025)

Serina Therapeutics (SER) has disclosed Depreciation and Depletion for 6 consecutive years, with $85000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion fell 61.01% to $85000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107000.0 through Dec 2025, down 57.03% year-over-year, with the annual reading at $85000.0 for FY2025, 61.01% down from the prior year.
  • Depreciation and Depletion hit $85000.0 in Q4 2025 for Serina Therapeutics, up from $22000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $218000.0 in Q4 2024 to a low of $13000.0 in Q1 2023.
  • Historically, Depreciation and Depletion has averaged $64500.0 across 3 years, with a median of $26500.0 in 2024.
  • Biggest five-year swings in Depreciation and Depletion: soared 138.46% in 2024 and later crashed 61.01% in 2025.
  • Year by year, Depreciation and Depletion stood at $18000.0 in 2023, then skyrocketed by 1111.11% to $218000.0 in 2024, then plummeted by 61.01% to $85000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for SER at $85000.0 in Q4 2025, $22000.0 in Q1 2025, and $218000.0 in Q4 2024.